GUIDELINES FOR THE REFERRAL OF SICKLE CELL AND THALASSAEMIA PRENATAL DIAGNOSIS SAMPLES TO MOLECULAR HAEMOGLOBINOPATHY LABORATORIES

01 May 2012 Version 2.4

CONTENTS

Introduction	2
Part One: Referral of Samples	2
Confirmation of risk) 2
Notifying the molecular haemoglobinopathy laboratory	2
Request form	3
Parental bloods	3
Fetal samples	4
	5
	5
Part Two: Outcome Data Collection Guidelines	6
Process to assess outcomes	6
Part Three: Laboratory Contact Lecails	7
Appendix 1 – PND Outcome Form: Part 1	9
Appendix 2 – PN Outcome Form: Part 2	10
Appendix 3 — Outcome Form: Flow Diagram	11
Appendix 4 CH Request form for Prenatal Diagnosis	12
Appendix 5 – UCLH Request from for Prenatal Diagnosis	
Appendix 6 – Oxford Request form for Prenatal Diagnois	15

INTRODUCTION

The NHS Sickle cell and thalaasaemia screening (SCT) programme was set up in 2001 with the aim to develop a linked high quality screening programme. During this time the screening programme has worked closely with the three molecular haemoglobinopathy laboratories to offer a high quality prenatal diagnostic service to at risk couples identified through screening. The programme has worked with the laboratories and regional teams to develop this set of guidelines for the referral and follow up of sickle cell and thalassaemia prenatal diagnosis samples to molecular haemoglobinopathy laboratories. The guidelines cover three areas:

Part One: Referral of samples

Part Two: Collection of Outcome data

Part Three: Laboratory contact details and referral forms

PART ONE: REFERRAL OF SAMPLES

CONFIRMATION OF RISK

Fetal sampling should only be carried out if the risk to the pregnancy is confirmed. In some instances this is straightforward e.g. risk of sickle cell disease when both parents are call of sickle cell, as sickle cell status can be easily confirmed by most routine diagnostic/screening haematology laboratories. Molecular confirmation of parental carrier status for alpha and beta thalassaemia is highly recommended prior to fetal sampling to identify the mutations involved.

If there is any doubt about the parental genotypes or whether further testing is required prior to fetal sampling, please contact the molecular haemoglobinopathy laboratory for advice.

NOTIFYING THE MOLECULAR HAEMOGLOBINOPATHY LABORATORY

The molecular haemoglobinopathy laboratory must be contacted in advance to make arrangements for the referral of a prenatal diagnosis sample. This ensures that the laboratory knows to expect the sample and can follow-up if the samples do not arrive at the appropriate time. See Part three of these guidelines for contact details of the laboratories.

REQUEST FORM

A fully completed prenatal diagnosis request form must accompany the fetal/ parental samples. Additional information such as antenatal screening results or genetic results from other laboratories should be included, particularly in the absence of a paternal sample. See Part three of these guidelines for copies of request forms.

PARENTAL BLOODS

Ideally new bloods from **both** parents in this prespancy (2 x 5 ml EDTA) should be sent with each prenatal diagnosis sample. These can either be sent to the molecular haemoglobinopathy laboratory ahead of the fetal sampling or in cases where the parental mutations are known (e.g. carriers of sickle cell) can be sent with the fetal sample.

Prenatal diagnosis is not possible without a maternal blood sample as this is required to confirm the maternal genotype and to exclude significant maternal DNA contamination of the fetal sample.

If the paternal generatory is known (i.e. the father has been previously tested in another laboratory) but he is currently unavailable for blood sampling, a copy of the father's laboratory results should be sent to the prenatal diagnosis laboratory so they can assess the fetal risk.

If the paternal genotype is unknown and he is unavailable for testing, prenatal diagnosis can still be carried out but the conditions that can and cannot be excluded will be complex and depend on factors such as maternal genotype, family origins etc. The potential risk to the fetus in such cases should be discussed carefully with the molecular laboratory **prior** to fetal sampling being undertaken. Results will usually be presented on a risk basis and extended testing may be required which could delay the turn around time. Mothers/ couples should be informed of possible timescales and delays by the responsible clinician.

New parental bloods must be taken in every prenatal diagnosis even if the couple have had prenatal diagnosis previously. This overcomes issues with insufficient samples being stored and pregnancies with different partners. If the father is unavailable for blood sampling and the referrer requires the haemoglobinopathy lab to use a stored paternal DNA sample then the referrer must contact the laboratory directly and confirm the details of the father for the current pregnancy in writing (preferably on the request form).

FETAL SAMPLES

CVS, amniotic fluid or fetal blood can be used to extract fetal DINA to carry out the prenatal diagnosis. In most instances sufficient DNA can be obtained from uncultured fetal material to obtain a diagnosis. This allows esults to be turned around within a few days (see below). However in some cases the obstetrician is only able to obtain a very small fetal sample, which may meant the sample will need to be cultured in order to obtain enough DNA to carry out the diagnosis. Parent's and health professionals must be aware that this eventuality will result in a much longer turnaround time for results as cultures normally require 10-14 days to grow.

CHORIONIC VILLUS BIOPSY SAMPLE (CVS)

The CVS must be cleaned by microscopic dissection to remove any contaminating maternal tissue before being used for fetal diagnosis. The referrer should arrange with their cytogenetics laboratory for the sample to be cleaned and forwarded by guaranteed past or courier to the molecular laboratory with the appropriate documentation (i.e. prenatal diagnosis request form). It is recommended that the cytogenetics lab sets up CVS back-up cultures in-case there is insufficient DNA in the un-cultured material to carry out the diagnosis. The molecular laboratory will contact the cytogenetic laboratory if and when the backup cultures are required.

AMNIOTIC FLUID SAMPLE

Obstetric departments should aim to take approximately 20 mls of amniotic fluid which can be split between the cytogenetic and molecular laboratories. 10mls should be forwarded directly to the molecular laboratory for testing and the remaining 10mls sent to a local cytogenetics laboratory for back-up cultures/ karyotyping.

(Alternatively, all the fetal sample can be sent to the cytogenetic laboratory for them to divide and send the sample to the molecular laboratory). The molecular laboratory will contact the cytogenetic laboratory if the backup cultures are required. If it is not possible for the obstetrician to obtain 20mls of amniotic fluid the molecular laboratory must be notified.

FETAL BLOOD

On very rare occasions fetal blood sampling may be performed and a fetal blood sample sent in EDTA for analysis.

TURN AROUND TIMES

If the parental genotypes are known the target turnaround for prehatal diagnosis is 3 working days upon receipt of the fetal sample in the molecular laboratory. If the parental mutations are not known prior to fetal biopsy then the turnaround time is likely to be longer.

Please note: this target time does not include sample preparation time, in cytogenetics laboratories or sample transit times which may vary between centres Also, if a fetal sample is small and cultured cells are required to complete the diagnosis then the turn-around time for results will be much longer as cultures normally require 10-14 days to grow (see section on fetal samples).

REPORTS

When the fetal diagnostic report is ready the main contact for results will be alerted and the report set then be sent via secure FAX or encrypted email. Hard copies of reports will then be sent out by post. It is important for referrers to be aware that all prenatal diagnosis results assume the stated family relationships to be true. The molecular lab assesses fetal risk and defines the appropriate genetic testing approach from the information supplied. Inaccuracies in stated relationships such as non-paternity can lead to a misdiagnosis.

As part of national quality assurance, all molecular laboratories report anonymised pregnancy outcome data on women that have undergone prenatal diagnosis for sickle cell and thalassaemia to the NHS Sickle cell and thalassaemia screening programme. This allows the prenatal and newborn screening results to be compared, as well as providing information on the choices made by families. The check with the newborn screening laboratory is done by the molecular PND laboratory but is only possible when information about the pregnancy outcome is provided by the maternity unit where the woman is booked.

PROCESS TO ASSESS OUTCOMES

A form to support collection of outcome data has been developed (see appendix One). This is a two part form that is sent by the molecular laboratory to the requesting clinician with the PND result. On receipt the requesting clinician should ensure:

- Part 1 is completed by screening co-ordinator or specialist nurse and returned to the molecular haemoglobinopathy laboratory within 1 month of the PND being reported. Internation on whether the pregnancy is continuing, has miscarried or been terminated is required.
- Part 2 is remarked by screening co-ordinator or specialist nurse until delivery, if the prespacey is on-going.
- Part 2 B is completed by the Screening co-ordinator or specialist nurse within one month of delivery and returned to molecular haemoglobinopathy laboratory. Information on the baby's date of birth, NHS number and place of birth is required. This allows the molecular haemoglobinopathy laboratory to contact the appropriate newborn screening laboratory to obtain the newborn screen result

This process is essential to compare and link the prenatal result with the newborn screening result. Maternity units and referral/tertiary centres should work together with the molecular laboratories to ensure that completed outcome data is returned to the molecular laboratory in a timely manner so that quality assessments across the pathway can be made.

PART THREE: LABORATORY CONTACT DETAILS

John Radcliffe Hospital Oxford

Contact Dr Shirley Henderson, Principal Clinical Scientist/Deputy Director

email: hbopathy.screening@nhs.net or molhaem@ouh.nhs.uk

Tel 01865 572769

Fax 01865 572775

Address: National Haemoglobinopathy Reference Laboratory

Molecular Haematology

Level 4

John Radcliffe Hospital

Oxford

OX3 9DU

Website with request form:

JEMBER 2011 http://www.oxfordradcliffe.nhs.uk/forp.fie departments/labs/haematology/molha em/haemoglobinopathies.aspx

age 15 of this document An example request form is give

King's College Hospita

Contact rk, Principal Clinical Scientist

email: @nhs.net

Tel

Tel lab

Fax 020 3299 1035

Address: Red Cell Centre

1st Floor Bessemer Wing

King's College Hospital

Denmark Hill

London SE5 9RS

Website: http://kingspath.co.uk/

http://kingspath.co.uk/tests/haematology/58/ Request form: available at and on page 12 of this document

University College London Hospital

Dr Mary Petrou, Director Haemoglobinopathy Genetics Centre Contact

email:

Tel 020 3447 9458

Fax 020 3447 9864

Address: 86-96 Chenies Mews

London WC1 E6HX

Paper copy of request form available on page 13 of this document



Dear requesting clinician,

Part A

As part of Quality Assurance, all PND laboratories are collecting pregnancy outcome data on women that have undergone prenatal diagnosis for sickle cell and Thalassaemia from 1 July 2008. The main aim is to link prenatal and newborn results. The linkage will be done by the PND lab, but the PND labs will require notification of the pregnancy outcome from the maternity unit where the woman is booked. To achieve this, can you send this outcome form to the screening co-ordinator or specialist nurse at the maternity unit where the woman was booked.


For more information on this work please contact the PND laboratory or the Sickle Cell and Thalassaemia Screening Programme Centre (020 7848 6634). Thank you very much for your help with this important work.

PND OUTCOME FORM (Part 1) - Short Term Pregnancy Outcome

Outcome Form Unique number:

- piease forward to red	questing unit		^ /	
Maternal Surname	First name	DoB	NHS Numb	EDD
Maternal Address		GP Name and	Address	PND reference
			.00	Т
			7	
			·	
	cut	here		
PND O	UTCOME FORM (t Term Pregnancy (Jutcome
THE		at 1 onor	remit regulation (Jacome
Part B To be complete	ad by the personing as	Outcome E	orm Unique number:	·
ordinator or specialist nu		Outcome F	omi omque mumber.	
lab within 1 month of rec		•		
Maternity Unit address		Date of refer	ral Referrers name	PND result
Materinty Offic address		Date of Telef	Tai Referrers fiame	FND lesuit
Diagon return to DNE) la Colvana:	Diagon rotu	rn by (one month fron	m data of DND requiti
Please return to PND	lab andless.	Flease retu	in by (one monun nor	ii dale di PND result)
	•			
Please tick outcome:				
Please tick outcome:			1	
	CONTINUING PI	-]	
	MISCARRIAGE		/ F 7#	
	TERMINATION (OF PREGNANC'	/ [] [^]	
* If there is a miscarriage	or termination of pregna	nev do not compl	oto Part Two of the outer	omo form
Completed by (please		ricy, do not compr	Date Part 1 B co	
Completed by (picasi	c print)		Date Fait FB 60	inpicted on
NAME				
TELEPHONE				

Please complete parts in blue, retain the named portion of this form (part 1 A), and return Part 1B - Short term Pregnancy Outcome form, with it's unique identifying number to the PND laboratory



PND OUTCOME FORM (Part 2) - Final Outcome

Part A - please forward to re-	questing unit	Outcome Form U	nique number: OXT	
Maternal Surname	First name	DoB	NHS Number	EDD
Maternal Address		GP Name and Ad	dress	PND reference
Maternity Unit		Date of referral	Referrers name	PND result
			,\\\-\ <u>\</u>	

PND OUTCOME FORM (Part 2) Final Outcome


Part B to be completed	within one month of	Outo	ne Form Uniqu	e number: O	XT
delivery by Screening C	co-ordinator or		•		
Specialist Nurse and retu	urned to PND lab				
Maternity Unit		Date of referral	Name of Refer	rer	EDD
Please return to PND	lab address		Please return l	oy (one monti	h from EDD)
Baby's NHS Number	Newborn laborato bloods oot was ser	•	Baby's place of birth	If no live bit give reason	
Completed by (please	e print)		Date Part 2 B	completed on	
NAME					
TELEPHONE					

Please complete parts in red, retain the named portion of this form (Part 2 A), and only return Part 2 B Final Outcome Form, with it's unique identifying number to the PND laboratory

Version 4 July 08



Flow Diagram for use of Two Part Pregnancy Outcome Form



The form should be sent be sent for all PND requests, not just those where PND shows an affected fetus.

The screening co-ordinator or specialist nurse is only required to complete parts in red and blue.

Version 4 July 08



complete Q18 of PND data return





Laboratory Contact details

Telephone: 020 3299 9000 Ext 2265 (lab) Telephone: 020 3299 4337 (Office)

Fax: 020 3299 1035

Section Email kch-tr.PND@nhs.net

Denmark Hill London SE5 9RS

Tel: 020 3299 9000 www.kingspath.co.uk www.kch.nhs.uk

KCH REQUEST FOR PRENATAL DIAGNOSIS

	Mother's details			Partne	er's details	
Surname						
Forename						
DOB						
NHS Number	r				Λ	
Ethnic Origin						
Genotype	For thal cases define mutation or state	e unknown.	Mutatio	on (please	e tick one)	
HbAS	(tick)		(tick)		1	
HbAC	(tick)		(tick)			
Beta						
thalassaemia				$\Delta \mathbf{V}$		
Alpha			•	SO'		
thalassaemia			<u>_,•</u>	7_		
Other				•		
	opies of all Haemoglobinopathy Screening the table below is for UK referrals only.	Add Add	ress:	atory (Fax	c no : 020 3299 1	1035)
Fetal Sample	type: CVS / AMNIC (please circle)	Maternal bloo	l taken:	Y/ N (pl	lease circle)	
Gestation at s	ampling:	Paternal blood	taken: `	Y/ N		
EDD or US ED	DD:	Blood sample	arri <u>ving</u>	with fetal	sample Y/ N	
		Sampled at: H	BR	GSTH	Other	
Prenatal Dia	gnosis Report to be sent to:	<u> </u>				
	PRIMARY REFERRER		CC	PY OF R	EPORT TO	
Name:		Name:				
Address:		Address	s:			
Tel:		Tel:				
Fax:		Fax:				

please note Fetal sampling will not take place AT THE HARRIS BIRTHRIGHT UNIT WITHOUT THE FOLLOWING: Hepatitas B / HIV / Rhesus status. Results to be faxed to: HBR Unit: (Fax: 020 7733 9534) or Laboratory: (Fax: 020 3299 1035)



NHS Foundation Trust

Haemoglobinopathy Genetics Centre	Telephone: 0845 155 5000 Ext.75230
Ground Floor	Direct Line: 020 3447 9458
86-96 Chenies Mews	Fax: 020 3447 9864
London WC1E 6HX	HaemGen@uclh.nhs.uk
	Ground Floor 86-96 Chenies Mews

Laboratory number			
<u>U</u>	CH Request Form: I	Prenatal Diagnosis of Haemoglol	oin Disorders
	Mother's Details:	Partner Details:	Mother's GP Details:
Surname:			
First name:			
Date of birth:			N/A
Address:			
Post Code:			
Booking Hospital:			
Hospital No:			
NHS Number:			
Ethnic Origin:			4
Parental Genotype:			
Any other relevant			
clinical information		<u>ე</u>	
-		<u> </u>	
	Referrer:	Report to.	Invoice to:
Name:			
Hospital:		·	
Address:			
Post Code:			
Tel No.			
Fax No.			
		<u>Netat Sample</u>	
Samples sent (please circ	(le) Maternal blood	eter al blood / CVS / CVS DNA / Amniotic flui	d / Fetal blood / Other (specify)
Sampling method (please		S, Transvaginal CVS, Amniocentesis, Fet	al blood sampling
Fetal Gestation	LMP:	EDD:	Age at Sampling:
Cytogenetic Lab Name		Cytogenetic Lab Tel No.	
Backup cultures in Progr	ess V/	Cytogenetic cleaning carried out	Y/N
(please circle)		(please circle)	I / IN

Sample and Information Requirements

Fetal samples: CVS samples should be sent in an isotonic transport medium such as culture medium. Amniotic fluid samples: at least 10mls should be sent. Fetal blood samples must be sent in EDTA tubes.

Parental samples: Blood samples should be sent with each prenatal diagnosis request. 10ml of EDTA blood labelled with patient's surname, first name, DOB, Hospital number and the date of sampling.

Information: Please provide full Blood Counts and HPLC / Hb Electrophoresis results for the patient, partner, and other relatives where applicable. Please complete ethnic origin form or give ethnic origin above.

Please send samples in appropriate packaging, with completed signed request form, patient information and copy of consent form, to the above address by guaranteed post or courier.

Please sign below to confirm that the patient and partner have given appropriate consent for:

- Testing
- Samples will be stored
- Made anonymous and used as controls and test development

Signed: Date:

Ethnic Origin Form


(To be completed by the referring health professional)

A)	MIXED	Patient	Baby's Father
Furth	ner information:		
(B)	WHITE		
Other	sh, Scottish, Welsh or Irish r North European ther White background		
(C)	MEDITERRANEAN		
Turki: Italiar	or Greek Cypriot sh or Turkish Cypriot n, Maltese ther Mediterranean background		
(D)	ASIAN	0	V
Pakis Bangl	n or African-Indian tani ladeshi other Asian background	OVENBER	
(E)	SOUTH EAST ASIAN	,07,	
Chine	ese		
Japan	ese dese Vietnamese or Filipino sysian or Indonesian other SE Asian background		
Thai,	Vietnamese or Filipino		
Malay	ysian or Indonesian		
Any o	other SE Asian background		
(F)	BLACK C		
Africa	an Y		
Carib	bean		
Any o	other Black background		
(G)	ARABIC		
Arab	African		
Irania	an		
Iraq			
Kurdi	ish		
Any o	other Arabic background		
(H)	DON'T KNOW		









NATIONAL HAEMOGLOBINOPATHY REFERENCE LABORATORY

Director: Dr John Old, FRCPath.

Deputy Director: Dr. Shirley Henderson. PhD.

Sample reception: 01865 572769 Sec: 01865 572826 Fax: 01865 572775 John Radcliffe Hospital
Email: molhaem@ouh.nhs.uk.

Website: www.ouh.nhs.uk/molhaem

Oxford, OX3 9DU

Surname:	Mother's details:		Partner's details:
		Surname:	
Forename:		Forename	
Date of birth:		Date of birth:	
Address:		Address	•
NHS number:		NHS number:	
Hosp No:		Hosp No:	0,
P Name and ddress:		2	. •
Referred by:		Report to:	
Name Address :		Table .	
Telephone INVOICE to be sen	CHINC	Telephone	
	D)	pling Details ypeFat	her's genotype
			VS DNA / Amniotic fluid / Fetal Bloo
Type of samples set Date/time of fetal s	ample	Gestation a	t sampling:,
Type of samples set Date/time of fetal s Cytogentics lab use Sample and Information: The samples: Frest r Information: http://	d for cleaning /culturing:: mation Requirements (full can be sent to a cytogenet by EDTA blood samples & FBC/HP	details are in our "info cics lab for cleaning /cultur LC results should be sent wents/departments/labs/haen	rmation for users" guide) ring before forwarding to us.


Genotype request form: v 7 Date issued: 28/02/12



Oxford Radcliffe Hospitals NHS







ETHNIC ORIGIN FORM

To be completed by the referring health professional

Α.	MIXED			
	Further information			
		Patient	Baby's Father	
B.	WHITE			
	English, Scottish, Welsh or Irish			
	Other North European			
	Any other white background			
C.	MEDITERRANEAN		\wedge	
	Greek or Greek Cypriot		0, -	
	Turkish or Turkish Cypriot			
	Italian, Maltese			
	Any other Mediterranean background			
D.	ASIAN	BE		
	Indian or African-Indian	<i>`\U.</i> □		
	Pakistani	✓ □		
	Bangladeshi			
	Any other Asian background			
E.	SOUTH FAST ASIAN			
	Chinese			
	Japanese			
	Thai, Vietnamese or Filipino			
	Malaysian or Indonesian			
	Any other SE Asian background			
F.	Chinese Japanese Thai, Vietnamese or Filipino Malaysian or Indonesian Any other SE Asian background BLACK African			
_				
	Caribbean			
	Any other black background			
G.	ARABIC			
	Arab African			
	Iranian			
	Iraq			
	Kurdish			
	Any other Arabic background			
н.	DON'T KNOW			
		_ _	_	